What is U-Oscine?
U-Oscine is an anticholinergic medicine. U-Oscine has many effects in the body including decreasing the secretion of fluids, slowing the stomach and intestines, and dilation of the pupils.
U-Oscine is used to relieve nausea, vomiting, and dizziness associated with motion sickness and recovery from anesthesia and surgery. U-Oscine may also be used in the treatment of parkinsonism, spastic muscle states, irritable bowel syndrome, diverticulitis, and other conditions.
U-Oscine may also be used for purposes other than those listed in this medication guide.
U-Oscine indications
U-Oscine transdermal system is indicated in adults for the prevention of:
- •
- nausea and vomiting associated with motion sickness.
- •
- post-operative nausea and vomiting (PONV) associated with recovery from anesthesia and/or opiate analgesia and surgery.
How should I use U-Oscine?
Use U-Oscine drops as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- U-Oscine drops is only for the eye. Do not get it in your nose or mouth.
- To use U-Oscine drops in the eye, first, wash your hands. Tilt your head back. Using your index finger, pull the lower eyelid away from the eye to form a pouch. Drop the medicine into the pouch and gently close your eyes. Immediately use your finger to apply pressure to the inside corner of the eyelid for 1 to 2 minutes. Do not blink. Remove excess medicine around your eye with a clean, dry tissue, being careful not to touch your eye. Wash your hands to remove any medicine that may be on them.
- To prevent germs from contaminating your medicine, do not touch the applicator tip to any surface, including the eye. Keep the container tightly closed.
- If you miss a dose of U-Oscine drops, use it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use U-Oscine drops.
Uses of U-Oscine in details
This medication is used to widen the pupils for eye examination or eye surgery. It is also used to decrease pain and swelling from an inflammation of the eye (iridocyclitis). It belongs to a class of drugs known as anticholinergics. U-Oscine works by blocking the effects of a certain natural chemical (acetylcholine) on certain eye muscles, causing relaxation of these muscles. This effect causes the pupil to widen and the lens to temporarily lose the ability to focus. U-Oscine decreases pain in eye inflammation by relaxing the eye muscles.
How to use U-Oscine ophthalmic
If you are using this medication for eye inflammation, apply it to the eye up to 3 or 4 times a day or as directed by your doctor. If you are using this medication to widen the pupil, it is usually applied in the eye 1 hour before the procedure/exam or as directed by your doctor. This medication is for use in the eye only. Do not take by mouth or inject.
To apply eye drops, wash your hands first. To avoid contamination, do not touch the dropper tip or let it touch your eye or any other surface.
If you are wearing contact lenses, remove them before using these eye drops. Ask your doctor when you can start wearing your contact lenses again.
Tilt your head back, look upward, and pull down the lower eyelid to make a pouch. Hold the dropper directly over your eye and place 1 drop into the pouch as directed by your doctor. Look downward and gently close your eyes for 1 to 2 minutes. Place one finger at the corner of your eye (near the nose) and apply gentle pressure for 2 to 3 minutes. This will prevent the medication from draining away from the eye and will also help reduce side effects. Try not to blink and do not rub your eye. Repeat these steps if your dose is for more than 1 drop or for your other eye if so directed. Wash your hands after applying eye drops.
If you are applying eye drops into a child's eyes, wash your hands and the child's hands afterwards. Be careful not to get any drops in the child's mouth.
Do not rinse the dropper. Replace the dropper cap after each use.
If you are using another kind of eye medication (e.g., drops or ointments), ask your doctor if you should continue to use them with this medication and when you should start them again. Use eye drops before eye ointments to allow the drops to enter the eye.
If you have been directed to use this medicine more than 1 time (e.g., for eye inflammation), use it regularly in order to get the most benefit from it. To help you remember, use it at the same time(s) each day. Continue using it for the full time prescribed.
This medication starts to work in minutes, and its effect usually lasts for several days or sometimes longer. Tell your doctor if you continue to have blurred vision, sensitivity to light, or widened pupils 1 week after your exam. If you are treating inflammation, tell your doctor if your condition does not improve or if it worsens.
U-Oscine description
An alkaloid from Solanaceae, especially Datura metel L. and Scopola carniolica. U-Oscine Hydrobromide Trihydrate and its quaternary derivatives act as antimuscarinics like atropine, but may have more central nervous system effects. Among the many uses are as an anesthetic premedication, in urinary incontinence, in motion sickness, as an antispasmodic, and as a mydriatic and cycloplegic.
U-Oscine dosage
U-Oscine Dosage
Applies to the following strength(s): 1.5 mg; 1 mg/mL; 0.4 mg/mL; 0.4 mg
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
Usual Adult Dose for:
- Nausea/Vomiting
- Motion Sickness
- Parkinsonian Tremor
Usual Pediatric Dose for:
- Nausea/Vomiting
- Motion Sickness
Additional dosage information:
- Renal Dose Adjustments
- Liver Dose Adjustments
- Precautions
- Dialysis
- Other Comments
Usual Adult Dose for Nausea/Vomiting
General antiemetic use: 0.3 to 0.65 mg administered IV, intramuscularly or subcutaneously every 6 to 8 hours as needed.
Post-operative nausea and vomiting use: apply one U-Oscine 1.5 mg transdermal disc behind the ear the evening before the scheduled surgery. The disc should remain in place for 24 hours after surgery before discarding.
If using U-Oscine transdermal on an obstetrics patient, apply the disc one hour prior to scheduled Cesarean section to limit exposure to the infant.
Usual Adult Dose for Motion Sickness
Apply one U-Oscine 1.5 mg transdermal disc behind the ear at least 4 hours prior to exposure every 3 days as needed.
Usual Adult Dose for Parkinsonian Tremor
0.4 to 0.8 mg orally every 8 hours as needed.
Usual Pediatric Dose for Nausea/Vomiting
1 to 12 years: 6 mcg/kg/dose (maximum dose: 0.3 mg/dose) administered IV, IM or subcutaneous every 6 to 8 hours as needed.
Usual Pediatric Dose for Motion Sickness
Greater than 12 years: apply one U-Oscine 1.5 mg transdermal disc behind the ear at least 4 hours prior to exposure every 3 days as needed.
Renal Dose Adjustments
Data not available
Liver Dose Adjustments
Data not available
Precautions
As with other anticholinergic agents, U-Oscine is contraindicated for patients with angle-closure glaucoma, prostatic hypertrophy, and pyloric obstruction. It should not be administered to patients with impaired hepatic or renal function.
U-Oscine may cause drowsiness, confusion, and disorientation. The elderly may be particularly sensitive to these effects. All patients should be cautioned against engaging in activities which require mental alertness, such as driving or operating dangerous machinery, while using the U-Oscine transdermal patch. The concomitant use of alcohol or other agents possessing CNS depressant activity should be avoided if possible.
U-Oscine may aggravate seizures (although this association has been disputed) and psychoses and should be used cautiously in patients with a history of such disorders.
Use with caution in patients with cardiac disease and in the elderly.
The safety and efficacy of U-Oscine in children have not been determined.
Dialysis
Data not available
Other Comments
U-Oscine transdermal patches contain residual drug when removed after being applied for 72 hours. Patients should wash their hands well with soap and water to prevent accidental transfer of U-Oscine to eyes or mucosal surfaces. Once removed, the patch should be folded against itself such that the adhesive side containing residual drug is not accessible.
Only one transdermal patch should be on the patient at any given time during therapy; remove the used disc prior to placing a fresh disc on the skin.
More about U-Oscine
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Interactions
- Support Group
- 92 Reviews - Add your own review/rating
Consumer resources
- U-Oscine
- U-Oscine patch
- U-Oscine transdermal
- U-Oscine Transdermal (Advanced Reading)
- Other brands: Transderm-Scop, U-Oscine, Maldemar
Professional resources
- U-Oscine (AHFS Monograph)
- More (3) »
Related treatment guides
- Parkinsonian Tremor
- Motion Sickness
- Nausea/Vomiting
U-Oscine interactions
See also:
What other drugs will affect U-Oscine?
The absorption of oral medications may be decreased during the concurrent use of U-Oscine because of decreased gastric motility and delayed gastric emptying.
U-Oscine Hydrobromide Trihydrate should be used with care in patients taking other drugs that are capable of causing CNS effects such as sedatives, tranquilizers, or alcohol. Special attention should be paid to potential interactions with drugs having anticholinergic properties; e.g., other belladonna alkaloids, antihistamines (including meclizine), tricyclic antidepressants, and muscle relaxants.
Laboratory Test Interactions
U-Oscine Hydrobromide Trihydrate will interfere with the gastric secretion test.
U-Oscine side effects
See also:
What are the possible side effects of U-Oscine?
Applies to U-Oscine: transdermal patch extended release
As well as its needed effects, U-Oscine (the active ingredient contained in U-Oscine) may cause unwanted side effects that require medical attention.
Major Side Effects
If any of the following side effects occur while taking U-Oscine, check with your doctor immediately:
Incidence not known:
- Blurred vision
- chest pain or discomfort
- difficulty with urinating
- dilation of the pupils
- dizziness, faintness, or lightheadedness when getting up from a lying or sitting position suddenly
- eye pain
- flushing or redness of the skin
- mood or mental changes
- muscle weakness
- nausea or vomiting
- rash
- redness of the white part of the eyes
- restlessness
- seeing, hearing, or feeling things that are not there
- shortness of breath
- slow or irregular heartbeat
- sweating
- unusual tiredness
- unusually warm skin
If any of the following symptoms of overdose occur while taking U-Oscine, get emergency help immediately:
Symptoms of overdose:
- Anxiety
- blurred or loss of vision
- change in consciousness
- decrease in frequency of urination
- decrease in urine volume
- difficulty in passing urine (dribbling)
- disturbed color perception
- double vision
- dry mouth
- dry, flushed skin
- fast, pounding, or irregular heartbeat or pulse
- halos around lights
- headache
- hyperventilation
- irritability
- loss of consciousness
- nervousness
- night blindness
- overbright appearance of lights
- painful urination
- pounding in the ears
- seizures
- shaking
- sleepiness
- trouble with sleeping
- tunnel vision
- unusual drowsiness, dullness, tiredness, weakness, or feeling of sluggishness
U-Oscine contraindications
See also:
What is the most important information I should know about U-Oscine?
Hypersensitivity to hyoscine-N-butylbromide, belladonna alkaloids or derivatives, or any other ingredients of U-Oscine.
Tablet: Patients with glaucoma, toxic megacolon (a very enlarged bowel), myasthenia gravis (a rare muscle wasting disease), obstructive prostatic hyperthropy (enlarged and blocked prostate), porphyria (hereditary blood disorder).
Patients who are pregnant, likely to become pregnant or breastfeeding, and children <6 years should not take hyoscine-N-butylbromide.
Injection: Patients with porphyria, untreated angle-closure glaucoma, prostatic enlargement, myasthenia gravis, and severe ulcerative colitis, or toxic megacolon, tachycardia; acute hemorrhage whose cardiovascular status is unstable; stomach or bowel obstruction, or in conditions where there is reduced bowel activity (eg, pyloroduodenal stenosis, achalasia), paralytic ileus or intestinal atony.
U-Oscine injection should not be given IM in patients being treated with anticoagulant therapy. Subcutaneous or IV routes may be used in these patients instead.
Active ingredient matches for U-Oscine:
Scopolamine in Thailand.
Unit description / dosage (Manufacturer) | Price, USD |
U-Oscine Injection 20 mg/1 mL x 1 mL x 50's | |
U-Oscine 10 mg x 100 x 10's | |
U-Oscine 10 mg x 1, 000's | |
List of U-Oscine substitutes (brand and generic names): | |
Thinthin (Taiwan) | |
Thinthin 10 mg | |
Tranaxine | |
Transcop (Italy) | |
Transderm Scop Patch | |
Transderm-V | |
Disc, Sustained Release; Transdermal; Scopolamine 1.5 mg (Novartis) | |
Travacalm HO (Australia) | |
Travel Calm (United Kingdom) | |
Tablet; Oral; Scopolamine Hydrobromide 0.3 mg (Boots) | |
Tropic Acid, Ester with Scopine | |
Uni Hioscin (Brazil) | |
Uospan (Thailand) | |
Uospan 10 mg x 50 x 10's | |
Uospan 10 mg x 1, 000's | |
Uricine (Thailand) | |
Uscosin (Romania) | |
Vacopan (Malaysia, Myanmar, Singapore, Thailand) | |
Vacopan 10 mg x 500's (Atlantic Lab) | |
Vacopan 20 mg/1 mL x 50's (Atlantic Lab) | |
Vacopan 20 mg/1 mL x 10's (Atlantic Lab) | |
Vacopan 20 mg/1 mL x 1 mL x 50's (Atlantic Lab) | |
Vacopan inj 20 mg/mL 50 x 1's (Atlantic Lab) | |
Vacopan tab 10 mg 500's (Atlantic Lab) | |
Vagotrope-S (Portugal) | |
Vascopan (Malaysia) | |
Vellios (Indonesia) | |
Vellios / amp 20 mg/1 mL x 5's | $ 7.75 |
Vescopolamine (Thailand) | |
Vesuton (Taiwan) | |
Vesuton 10 mg x 1000's | |
Vesuton 10 mg x 100 x 10's | |
Vhesyn (Philippines) | |
Vhesyn / amp 20 mg/1 mL x 1 mL x 10's | |
Vidaspan (Hong Kong) | |
Vivika (Taiwan) | |
Vorigeno (Spain) | |
We-Wang (Taiwan) | |
We-Wang 2 mg | |
Weiernin (Taiwan) | |
Weiernin 2 mg | |
Weilin (Taiwan) | |
Weilin 2 mg | |
Xemol (Turkey) | |
XSPAS (Philippines) | |
XSPAS Injection / 20mg per ml / 1ml units (Neon Laboratories Ltd) | $ 0.08 |
Xspas 20mg INJ / 1ml (Neon Laboratories Ltd) | $ 0.08 |
20 mg x 1ml (Neon Laboratories Ltd) | $ 0.08 |
Xspas 20 mg Injection (Neon Laboratories Ltd) | $ 0.12 |
Xspas 250 mg Injection (Neon Laboratories Ltd) | $ 1.43 |
XSPAS inj 20 mg x 1ml (Neon Laboratories Ltd) | $ 0.08 |
Xspas 20mg INJ / 1ml (Neon Laboratories Ltd) | $ 0.08 |
Xspas 10mg Tablet (Neon Laboratories Ltd) | $ 0.04 |
See 627 substitutes for U-Oscine |
References
- DailyMed. "SCOPOLAMINE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "scopolamine". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "scopolamine". http://www.drugbank.ca/drugs/DB00747 (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for U-Oscine are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking U-Oscine. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology